What is the recommended dosing regimen for Qulipta (atogepant) for migraine prevention, including adjustments for CYP3A4 interactions and renal or hepatic impairment?

Qulipta (Atogepant) Dosing for Migraine Prevention

Standard Dosing Regimens

For episodic migraine, the recommended dosage is 10 mg, 30 mg, or 60 mg taken orally once daily with or without food. 1

For chronic migraine, the recommended dosage is 60 mg taken orally once daily with or without food. 1

---

Dose Adjustments for CYP3A4 Inhibitors

Strong CYP3A4 Inhibitors (e.g., itraconazole, ketoconazole, clarithromycin)

• Episodic migraine: Reduce dose to 10 mg once daily when co-administered with strong CYP3A4 inhibitors 1
• Chronic migraine: Avoid concomitant use of strong CYP3A4 inhibitors with Qulipta 1
• Strong CYP3A4 inhibitors significantly increase atogepant exposure, necessitating dose reduction or avoidance 1, 2

Moderate or Weak CYP3A4 Inhibitors

• No dosage adjustment needed for episodic or chronic migraine 1

---

Dose Adjustments for CYP3A4 Inducers

Strong CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin)

• Episodic migraine: Increase dose to 30 mg or 60 mg once daily when co-administered with strong CYP3A4 inducers 1
• Chronic migraine: Avoid concomitant use of strong CYP3A4 inducers with Qulipta 1
• Strong CYP3A4 inducers significantly decrease atogepant exposure, requiring dose escalation or avoidance 1, 2

Moderate CYP3A4 Inducers

• Episodic migraine: Increase dose to 30 mg or 60 mg once daily 1
• Chronic migraine: Avoid concomitant use 1

Weak CYP3A4 Inducers (e.g., topiramate)

• Episodic migraine: Increase dose to 30 mg or 60 mg once daily when co-administered with weak CYP3A4 inducers 1
• Chronic migraine: Avoid concomitant use 1
• Even weak inducers like topiramate decrease atogepant exposure, requiring dose adjustment 1, 2

---

Dose Adjustments for OATP Inhibitors (e.g., single-dose rifampin, cyclosporine)

Episodic Migraine

• Reduce dose to 10 mg or 30 mg once daily when co-administered with OATP inhibitors 1

Chronic Migraine

• Reduce dose to 30 mg once daily when co-administered with OATP inhibitors 1
• OATP inhibitors significantly increase atogepant exposure, necessitating dose reduction 1, 2

---

Dose Adjustments for Renal Impairment

Mild to Moderate Renal Impairment

• No dosage adjustment required for episodic or chronic migraine 1, 2

Severe Renal Impairment or End-Stage Renal Disease (ESRD)

• Episodic migraine: Reduce dose to 10 mg once daily 1
• Chronic migraine: Avoid use in severe renal impairment or ESRD 1
• Atogepant pharmacokinetics are not significantly altered in mild to moderate renal impairment, but severe impairment requires dose reduction or avoidance 2, 3, 4

---

Dose Adjustments for Hepatic Impairment

Mild Hepatic Impairment (Child-Pugh A)

• No dosage adjustment required for episodic or chronic migraine 5, 4

Moderate Hepatic Impairment (Child-Pugh B)

• No dosage adjustment required for episodic or chronic migraine 5, 4
• Atogepant systemic exposure increases by 15-38% in moderate hepatic impairment, but this is not clinically significant given the established safety profile 5

Severe Hepatic Impairment (Child-Pugh C)

• No dosage adjustment required for episodic or chronic migraine 5, 4
• Severe hepatic impairment decreases atogepant clearance by approximately 37%, but single-dose studies showed no clinically relevant changes in pharmacokinetics 2, 5

---

Common Pitfalls and Caveats

Drug-Drug Interaction Complexity

• Do not confuse single-dose rifampin (OATP inhibitor) with steady-state rifampin (strong CYP3A4 inducer): Single-dose rifampin increases atogepant exposure and requires dose reduction, whereas steady-state rifampin decreases exposure and requires dose escalation or avoidance 1, 2

Chronic Migraine Restrictions

• Chronic migraine has stricter drug interaction restrictions: Avoid strong CYP3A4 inhibitors, all CYP3A4 inducers (strong, moderate, and weak), and use reduced doses with OATP inhibitors 1

No Adjustment for Common Medications

• No dose adjustment needed for concomitant use of P-glycoprotein inhibitors, BCRP inhibitors, oral contraceptives, famotidine, esomeprazole, sumatriptan, acetaminophen, or naproxen 2

Intrinsic Factors

• Age, sex, race, and body weight do not require dose adjustments 2, 6

---

Safety Considerations

Most Common Adverse Reactions

• Nausea (6-9%), constipation (6-8%), and fatigue/somnolence (4-5%) are the most common adverse reactions, occurring at rates greater than placebo 1

Hypersensitivity

• Contraindicated in patients with known hypersensitivity to atogepant, including anaphylaxis, dyspnea, rash, pruritus, urticaria, or facial edema 1

Liver Enzyme Elevations

• Transaminase elevations >3× upper limit of normal occurred in 0.9% of patients (similar to placebo at 1.2%) and were asymptomatic, resolving within 8 weeks of discontinuation 1

Weight Loss

• 5.3% of patients on 60 mg experienced ≥7% weight decrease at any point during treatment 1